Skip to content

TuHURA Biosciences, Inc. HURA Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

CTO
Citius Oncology, Inc.CTOR
-$3.83M-179%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s cash provided by (used in) operating activity, including discontinued operation?
TuHURA Biosciences, Inc. (HURA) reported cash provided by (used in) operating activity, including discontinued operation of -$4.41M in Q1 2026.
How has TuHURA Biosciences, Inc.'s cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
TuHURA Biosciences, Inc.'s cash provided by (used in) operating activity, including discontinued operation increased by 6.9% year-over-year, from -$4.74M to -$4.41M.
What does cash provided by (used in) operating activity, including discontinued operation mean?
Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.